Caron F, Ducrotte P, Lerebours E, Colin R, Humbert G, Denis P
Maladies Infectieuses et Tropicales, Hôpital Charles Nicolle, Rouen, France.
Antimicrob Agents Chemother. 1991 Jun;35(6):1085-8. doi: 10.1128/AAC.35.6.1085.
The amoxicillin-clavulanate combination (Augmentin) frequently induces gastric complaints and diarrhea by an unknown mechanism. The aim of this study was to assess the effects of two orally therapeutic regimens of amoxicillin-clavulanate on small bowel motility in human beings. Duodeno-jejunal manometric recordings were performed in six healthy subjects treated in a cross-over double-blind study with placebo; amoxicillin-clavulanate, 1 g plus 250 mg per os every 12 h for 3 days; or amoxicillin-clavulanate, 1 g plus 250 mg per os every 12 h on day 3 only (1-day regimen). Recordings were all performed on day 3 during a diurnal fasting period, a fed state after a standard dinner, and a nocturnal fasting period. Amoxicillin-clavulanate did not affect the motility of the small intestine during the diurnal fast or the fed state. During the nocturnal fast, amoxicillin-clavulanate significantly increased the motility index of the nonpropagated contractions and tended to increase the duration and the amplitude of the propagated contractions. The same digestive motor effect was already observed on the first day of treatment (1-day regimen). This study demonstrates that the oral administration of a therapeutic regimen of amoxicillin-clavulanate is associated, in most cases, with the occurrence of small intestinal motor disturbances.
阿莫西林-克拉维酸联合制剂(奥格门汀)常通过未知机制引发胃部不适和腹泻。本研究旨在评估两种口服阿莫西林-克拉维酸治疗方案对人体小肠运动的影响。在一项交叉双盲研究中,对6名健康受试者进行十二指肠-空肠测压记录,受试者分别接受安慰剂、阿莫西林-克拉维酸(每12小时口服1克加250毫克,共3天)或仅在第3天接受阿莫西林-克拉维酸(每12小时口服1克加250毫克,1天治疗方案)治疗。记录均在第3天的日间禁食期、标准晚餐后的进食状态以及夜间禁食期进行。阿莫西林-克拉维酸在日间禁食或进食状态下不影响小肠运动。在夜间禁食期间,阿莫西林-克拉维酸显著增加了非传播性收缩的运动指数,并倾向于增加传播性收缩的持续时间和幅度。在治疗的第一天(1天治疗方案)就已观察到相同的消化运动效应。本研究表明,在大多数情况下,口服阿莫西林-克拉维酸治疗方案与小肠运动紊乱的发生有关。